Predicting early treatment discontinuation and effectiveness in bevacizumab-treated patients with advanced ovarian cancer: Exploratory analyses of the OTILIA study (on behalf of NOGGO)

Wimberger, P., Woopen, H., Mustea, A., Oskay-Oezcelik, G., Keller, M., Harde, J., Richter, R., Wegenaer, A., Klawitter, S., Tomé, O., Sehouli, J., 2017.

ESGO7–0321 (PS19)

Studie: OTILIA; Indikation: Sonstige; Jahr: 2017; Veranstaltung: ESGO; Journal: -

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com